GlaxoSmithKline plc (GSK.L)
| Previous close | 1,325.00 |
| Open | 1,330.80 |
| Bid | 1,326.20 x 0 |
| Ask | 1,326.80 x 0 |
| Day's range | 1,318.40 - 1,344.20 |
| 52-week range | 1,280.92 - 2,746.59 |
| Volume | |
| Avg. volume | 10,939,171 |
| Market cap | 53.95B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 11.64 |
| EPS (TTM) | 1.14 |
| Earnings date | 02 Nov 2022 |
| Forward dividend & yield | 0.86 (6.57%) |
| Ex-dividend date | 18 Aug 2022 |
| 1y target est | N/A |
- Reuters
GSK selects Burberry's Brown as its first female CFO
(Reuters) -Britain's GSK has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. With Emma Walmsley as GSK's chief executive, Brown's appointment also creates a rare, all-female top management at a blue-chip British company and a global pharma major. Brown, who has extensive experience in the health and pharmaceutical industry, will join GSK from luxury fashion brand Burberry, in April and take up the job in May.
- Sky News
GSK poaches Burberry CFO to create all-female top team
GSK, the FTSE-100 pharmaceuticals giant, has poached Burberry Group's finance chief to create a rare all-female executive leadership team in London's blue-chip share index. Sky News has learnt that GSK could announce as soon as Monday morning that it has recruited Julie Brown to replace Iain Mackay, who has served as its chief financial officer since 2019. The appointment of Ms Brown comes during a period of seismic change for GSK, which demerged its consumer healthcare business - now called Haleon - in a £30bn deal in July.
- Zacks
Spero (SPRO) Skyrockets 168% on Licensing Deal With GSK
The exclusive licensing agreement with GSK will fund Spero's (SPRO) existing operations and extend its current cash runway beyond 2024.
